(Reuters) – GSK Plc will buy Canada-based late-stage biopharma company Bellus Health Inc in an all-cash deal for $2 billion, the companies said in a joint statement on Tuesday.
GSK’s offer of $14.75 per share is more than double Bellus’s closing price of $7.26 on the Nasdaq on Monday.
The acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with refractory chronic cough (RCC).
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Savio D’Souza)
